News

Using endoscopic or microscopic techniques to surgically remove the pituitary glands leads to similar remission and recurrence rates in Cushing’s disease patients, a review of 24 studies shows. The study, titled “Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing’s disease,” was published in the journal…

This week marks the launch of the “7,000 Mile Rare Movement,” a nationwide effort to raise money for research into the 7,000 known rare diseases that afflict at least 30 million Americans. The campaign kicks off Feb. 1 and culminates with Rare Disease Day on Feb. 28. Organized by…

Stereotactic radiosurgery – a type of targeted, high-dose radiation therapy – delivered with CyberKnife technology effectively induces remission in Cushing’s disease patients whose condition persisted after surgical removal of their pituitary glands. However, researchers advise, caution when interpreting the findings. While promising, the study included only a small group of patients analyzed retrospectively.

The minimally invasive laparoscopic adrenalectomy (LA) is a safe and feasible procedure for larger adrenal tumors and metastasis, a new Italian study shows. While the findings suggest that the surgical application of laparoscopic adrenalectomy could be extended, surgeons should undergo a 30-procedure learning curve to improve surgical outcomes, researchers say.

Excessive use of skin-applied steroids to manage diaper rash can lead to an infant developing  Cushing’s syndrome, a case study reports. Cushing’s is characterized by elevated levels of hormones known as glucocorticoids, typically due to malfunctioning of pituitary or adrenal glands. Skin-applied corticosteroid-based therapies, known as topical steriods, are used…

Addressing how a tissue absorbs and releases the contrast agent used in computed tomography (CT) scans – called a wash-out analysis – may help researchers determine if a tumor in the adrenal gland is benign or malignant, especially in the case of cortisol overproduction. This findings, reported in the study, “…

Strongbridge Biopharma is expecting a second patent on its Cushing’s syndrome therapy Recorlev (levoketoconazole). The signal it received was the U.S. Patent and Trademark Office completing a review of its new patent application for the cortisol synthesis inhibitor. The second patent, which would expire Jan. 10, 2026, would cover other conditions in…

The level of decline in blood cortisol levels in the immediate period after transsphenoidal surgery for Cushing’s disease may help predict which patients will achieve long-term disease remission. The study, “Earlier post-operative hypocortisolemia may predict durable remission from Cushing’s Disease” was published in the European Journal…

Therapies known as histone deacetylase inhibitors reduced fatty liver disease in a rat model of Cushing’s syndrome, a study reports. (HDACi) was found to reduce hepatic steatosis – also known as fatty liver disease – in a rat model of Cushing’s syndrome, according to a new study. Researchers’ article, “Histone…

Lower muscle mass and higher visceral fat are correlated to higher cortisol levels, and can be used as reliable biomarkers to assess disease severity in patients with adrenal adenomas, a new study shows. The study, “Impact of hypercortisolism on skeletal muscle mass and adipose tissue mass in…